The first step in the application of our pipeline consisted of the creation of the PKN, a static and genotype-agnostic map recapitulating the signaling pathways deregulated over AML tumor development and progression (Figure 2—figure supplement 1). This evidence concerns the gene PKN1 and acute myeloid leukemia.